Management of SARS-CoV-2 Infection: Key Focus in Macrolides Efficacy for COVID-19

Detalhes bibliográficos
Autor(a) principal: Batiha, GES
Data de Publicação: 2021
Outros Autores: Zayed, MA, Awad, AA, Shaheen, HM, Mustapha, S, Herrera-Calderon, O, Pagnossa, JP, Algammal, AM, Zahoor, M, Adhikari, A, Pandey, I, Elazab, ST, Rengasamy, KRR, Martins, N, Hetta, HF
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: https://hdl.handle.net/10216/152481
Resumo: Macrolides (e.g., erythromycin, fidaxomicin, clarithromycin, and azithromycin) are a class of bacteriostatic antibiotics commonly employed in medicine against various gram-positive and atypical bacterial species mostly related to respiratory tract infections, besides they possess anti-inflammatory and immunomodulatory effects. Coronavirus Disease 2019 (COVID-19) is an infectious disease caused by the severe acute respiratory syndrome of coronavirus 2 (SARS-CoV-2). It was first detected in Wuhan, Hubei, China, in December 2019 and resulted in a continuing pandemic. Macrolides have been extensively researched as broad adjunctive therapy for COVID-19 due to its immunostimulant abilities. Among such class of drugs, azithromycin is described as azalide and is well-known for its ability to decrease the production of pro-inflammatory cytokines, including matrix metalloproteinases, tumor necrosis factor-alpha, interleukin (IL)-6, and IL-8. In fact, a report recently published highlighted the effectiveness of combining azithromycin and hydroxychloroquine for COVID-19 treatment. Indeed, it has been underlined that azithromycin quickly prevents SARS-CoV-2 infection by raising the levels of both interferons and interferon-stimulated proteins at the same time which reduces the virus replication and release. In this sense, the current review aims to evaluate the applications of macrolides for the treatment of COVID-19.
id RCAP_436ef216ac28fc6cf642aa2919a6f48e
oai_identifier_str oai:repositorio-aberto.up.pt:10216/152481
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Management of SARS-CoV-2 Infection: Key Focus in Macrolides Efficacy for COVID-19AzithromycinCOVID-19EfficacyMacrolidesSARS-CoV-2 infectionMacrolides (e.g., erythromycin, fidaxomicin, clarithromycin, and azithromycin) are a class of bacteriostatic antibiotics commonly employed in medicine against various gram-positive and atypical bacterial species mostly related to respiratory tract infections, besides they possess anti-inflammatory and immunomodulatory effects. Coronavirus Disease 2019 (COVID-19) is an infectious disease caused by the severe acute respiratory syndrome of coronavirus 2 (SARS-CoV-2). It was first detected in Wuhan, Hubei, China, in December 2019 and resulted in a continuing pandemic. Macrolides have been extensively researched as broad adjunctive therapy for COVID-19 due to its immunostimulant abilities. Among such class of drugs, azithromycin is described as azalide and is well-known for its ability to decrease the production of pro-inflammatory cytokines, including matrix metalloproteinases, tumor necrosis factor-alpha, interleukin (IL)-6, and IL-8. In fact, a report recently published highlighted the effectiveness of combining azithromycin and hydroxychloroquine for COVID-19 treatment. Indeed, it has been underlined that azithromycin quickly prevents SARS-CoV-2 infection by raising the levels of both interferons and interferon-stimulated proteins at the same time which reduces the virus replication and release. In this sense, the current review aims to evaluate the applications of macrolides for the treatment of COVID-19.Frontiers Media20212021-01-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttps://hdl.handle.net/10216/152481eng2296-858X10.3389/fmed.2021.642313Batiha, GESZayed, MAAwad, AAShaheen, HMMustapha, SHerrera-Calderon, OPagnossa, JPAlgammal, AMZahoor, MAdhikari, APandey, IElazab, STRengasamy, KRRMartins, NHetta, HFinfo:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-11-29T15:47:59Zoai:repositorio-aberto.up.pt:10216/152481Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-20T00:32:29.250332Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Management of SARS-CoV-2 Infection: Key Focus in Macrolides Efficacy for COVID-19
title Management of SARS-CoV-2 Infection: Key Focus in Macrolides Efficacy for COVID-19
spellingShingle Management of SARS-CoV-2 Infection: Key Focus in Macrolides Efficacy for COVID-19
Batiha, GES
Azithromycin
COVID-19
Efficacy
Macrolides
SARS-CoV-2 infection
title_short Management of SARS-CoV-2 Infection: Key Focus in Macrolides Efficacy for COVID-19
title_full Management of SARS-CoV-2 Infection: Key Focus in Macrolides Efficacy for COVID-19
title_fullStr Management of SARS-CoV-2 Infection: Key Focus in Macrolides Efficacy for COVID-19
title_full_unstemmed Management of SARS-CoV-2 Infection: Key Focus in Macrolides Efficacy for COVID-19
title_sort Management of SARS-CoV-2 Infection: Key Focus in Macrolides Efficacy for COVID-19
author Batiha, GES
author_facet Batiha, GES
Zayed, MA
Awad, AA
Shaheen, HM
Mustapha, S
Herrera-Calderon, O
Pagnossa, JP
Algammal, AM
Zahoor, M
Adhikari, A
Pandey, I
Elazab, ST
Rengasamy, KRR
Martins, N
Hetta, HF
author_role author
author2 Zayed, MA
Awad, AA
Shaheen, HM
Mustapha, S
Herrera-Calderon, O
Pagnossa, JP
Algammal, AM
Zahoor, M
Adhikari, A
Pandey, I
Elazab, ST
Rengasamy, KRR
Martins, N
Hetta, HF
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Batiha, GES
Zayed, MA
Awad, AA
Shaheen, HM
Mustapha, S
Herrera-Calderon, O
Pagnossa, JP
Algammal, AM
Zahoor, M
Adhikari, A
Pandey, I
Elazab, ST
Rengasamy, KRR
Martins, N
Hetta, HF
dc.subject.por.fl_str_mv Azithromycin
COVID-19
Efficacy
Macrolides
SARS-CoV-2 infection
topic Azithromycin
COVID-19
Efficacy
Macrolides
SARS-CoV-2 infection
description Macrolides (e.g., erythromycin, fidaxomicin, clarithromycin, and azithromycin) are a class of bacteriostatic antibiotics commonly employed in medicine against various gram-positive and atypical bacterial species mostly related to respiratory tract infections, besides they possess anti-inflammatory and immunomodulatory effects. Coronavirus Disease 2019 (COVID-19) is an infectious disease caused by the severe acute respiratory syndrome of coronavirus 2 (SARS-CoV-2). It was first detected in Wuhan, Hubei, China, in December 2019 and resulted in a continuing pandemic. Macrolides have been extensively researched as broad adjunctive therapy for COVID-19 due to its immunostimulant abilities. Among such class of drugs, azithromycin is described as azalide and is well-known for its ability to decrease the production of pro-inflammatory cytokines, including matrix metalloproteinases, tumor necrosis factor-alpha, interleukin (IL)-6, and IL-8. In fact, a report recently published highlighted the effectiveness of combining azithromycin and hydroxychloroquine for COVID-19 treatment. Indeed, it has been underlined that azithromycin quickly prevents SARS-CoV-2 infection by raising the levels of both interferons and interferon-stimulated proteins at the same time which reduces the virus replication and release. In this sense, the current review aims to evaluate the applications of macrolides for the treatment of COVID-19.
publishDate 2021
dc.date.none.fl_str_mv 2021
2021-01-01T00:00:00Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://hdl.handle.net/10216/152481
url https://hdl.handle.net/10216/152481
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 2296-858X
10.3389/fmed.2021.642313
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Frontiers Media
publisher.none.fl_str_mv Frontiers Media
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799136233943728128